Actualités - Nuvaira

First patients successfully treated in the Nuvaira AIRFLOW-3 COPD pivotal trial

juillet 9, 2019/dans newsroom @fr, Non classifié(e) /par eric iverson

A first for Temple University Hospital and U.S. Patients MINNEAPOLIS, June 10, 2019 – Nuvaira, developer of novel therapeutic strategies to treat obstructive lung diseases, announced the first treatments in the AIRFLOW-3 pivotal trial, the first interventional COPD trial to target reduction in COPD exacerbations as a primary endpoint. Two U.S. patients were successfully treated […]

Nuvaira Receives French Innovation Funding for AIRFLOW-3 Pivotal Trial

mai 7, 2019/dans newsroom @fr, Non classifié(e) /par Amy Wolter

Novel program provides reimbursement for TLD therapy in France MINNEAPOLIS, April 28, 2019 – Nuvaira, developer of novel therapeutic strategies to treat obstructive lung diseases, has received acceptance from the Haute Autorité de Santé (HAS, the French health technology assessment agency) into its Forfait Innovation program. The program is designed to fast-track novel medical devices […]

Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking Treatment of COPD

février 12, 2019/dans newsroom @fr, Non classifié(e) /par Amy Wolter

Market Development Veteran Lisa Rogan Joins Nuvaira’s Executive Team MINNEAPOLIS, Feb 11, 2019 – Nuvaira, a developer of novel therapeutic medical devices to treat obstructive lung diseases, announced today it has closed a $79 million equity financing led by U.S. Venture Partners, with Endeavour Vision, Qiming Venture Partners, Lightstone Ventures and Richard King Mellon Foundation […]